Bian Dongliang, Zhao Liting, Zhang Xuelin, Lv Fanzhen, Zhu Zhenghong, Qiu Hui, Zhang Huibiao
Department of Thoracic Surgery, Fudan University Affiliated Huadong Hospital, Shanghai 200040, China.
Department of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Gland Surg. 2020 Apr;9(2):291-299. doi: 10.21037/gs.2020.03.01.
Thymomas are rare malignancies. Thymectomy is the optimal therapy which could prolong the survival of patients. However, prognostic factors of thymomas are not clear.
Thymomas patients were enrolled from 2001 to 2016. Clinical and pathological prognostic factors of thymomas were evaluated by univariate and multivariate analyses.
A total number of 98 patients was eligible for this study. All patients were received complete resection (CR). Diagnostic age [elder than the median 60 . younger than 60, hazard ratio (HR) =2.325, P=0.027], Masaoka stage (III I, HR =10.756, P<0.001; IV . I, HR =6.558, P=0.014), and diabetes mellitus (DM) (with without, HR =0.142, P=0.004) were independent prognostic factors for overall survival (OS). Immunohistochemistry (IHC) biomarker TP53 expression also influenced OS significantly (positive negative, HR =5.157, P=0.018). Furthermore, age (elder than 60 . younger than 60, HR =2.980, P=0.022) was independent prognostic factors for recurrence free survival (RFS).
We found that diagnostic age, clinical stages, DM, TP53 expression in IHC, and quality perioperative nursing are prognostic factors in thymomas.
胸腺瘤是罕见的恶性肿瘤。胸腺切除术是可延长患者生存期的最佳治疗方法。然而，胸腺瘤的预后因素尚不清楚。
纳入2001年至2016年的胸腺瘤患者。通过单因素和多因素分析评估胸腺瘤的临床和病理预后因素。
共有98例患者符合本研究条件。所有患者均接受了完整切除（CR）。诊断时年龄[大于中位数60岁、小于60岁，风险比（HR）=2.325，P=0.027]、Masaoka分期（III期对I期，HR =10.756，P<0.001；IV期对I期，HR =6.558，P=0.014）以及糖尿病（DM）（有对无，HR =0.142，P=0.004）是总生存期（OS）的独立预后因素。免疫组织化学（IHC）生物标志物TP53表达也对OS有显著影响（阳性对阴性，HR =5.157，P=0.018）。此外，年龄（大于60岁对小于60岁，HR =2.980，P=0.022）是无复发生存期（RFS）的独立预后因素。
我们发现诊断时年龄、临床分期、DM、IHC中的TP53表达以及围手术期优质护理是胸腺瘤的预后因素。
